- Home
- AFCG vs KRRO Comparison
AFCG vs KRRO Comparison
Compare AFCG & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AFCG | KRRO |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.9M | 58.6M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AFCG | KRRO |
|---|---|---|
| Price | $2.89 | $7.02 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $5.75 | ★ $74.17 |
| AVG Volume (30 Days) | 209.6K | ★ 1.1M |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | ★ 20.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,371,000.00 |
| Revenue This Year | N/A | $144.83 |
| Revenue Next Year | $4.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.52 | $5.20 |
| 52 Week High | $9.71 | $55.89 |
Technical Indicators
Market Signals| Indicator | AFCG | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 27.15 |
| Support Level | $2.52 | $5.20 |
| Resistance Level | $3.02 | $6.59 |
| Average True Range (ATR) | 0.16 | 0.51 |
| MACD | 0.04 | 0.75 |
| Stochastic Oscillator | 59.89 | 89.19 |
Price Performance
Historical ComparisonAbout AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is a commercial mortgage REIT that provides institutional loans to cannabis operators in the U.S. Through the management team's deep network and related credit and cannabis expertise. The company originates, structures, and underwrites loans secured by quality real estate assets, license value, and cash flows.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.